Letter to the Editor Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 27, 2024; 16(1): 109-111
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.109
Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients
Yu-Tong Sun, Qian-Qian Chen, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing 100193, China
ORCID number: Qian-Qian Chen (0009-0006-9078-5711).
Author contributions: Sun YT drafted the article; Chen QQ made critical revisions related to important intellectual content of the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qian-Qian Chen, MD, Associate Chief Physician, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100193, China. qian_qian_chen@163.com
Received: October 30, 2023
Peer-review started: October 30, 2023
First decision: November 22, 2023
Revised: December 4, 2023
Accepted: January 12, 2024
Article in press: January 12, 2024
Published online: January 27, 2024

Abstract

This letter comments on the article which reported that tenofovir alafenamide may increase blood lipid levels compared with entecavir in patients with chronic hepatitis B published on World J Hepatol 2023 August 27. We review the related research content, topic selection, methodology, conclusions, strengths and weaknesses of this article. And evaluate it in relation to other published relevant articles.

Key Words: Tenofovir alafenamide, Entecavir, Serum lipid levels, Hepatitis B virus

Core Tip: With the significant increase in the incidence of nonalcoholic fatty liver disease (NAFLD) in China, the number of patients with co-morbid chronic hepatitis B (CHB) and NAFLD has gradually increased. This letter comments on a published study which showned that CHB patients treated with tenofovir alafenamide (TAF) had higher levels of total cholesterol than CHB patients treated with entecavir; however, TAF-induced dyslipidemia did not increase the incidence of NAFLD. We comment on the article.



TO THE EDITOR

The prevalence of nonalcoholic fatty liver disease (NAFLD) in China has increased significantly in recent decades, giving rise to co-morbid chronic hepatitis B (CHB) and NAFLD in some patients. Many patients with hepatitis B virus (HBV) infection require long-term antiviral drugs such as tenofovir alafenamide (TAF) and entecavir (ETV), which are recommended as first-line agents in the guideline of HBV treatment. It has been shown that TAF has a lipid-enhancing effect in patients with human immunodeficiency virus (HIV) infection. However, A comparison of the effects of TAF and ETV on lipid patients with HBV has not yet been investigated.

The aim of this letter is to discuss the effects of TAF on blood lipid levels and the risk of developing NAFLD in CHB patients, and to compare changes in lipid levels before and after antiviral therapy with TAF or ETV.

We have read with interest the article published on World J Hepatol by Lai et al[1]. In this study, 336 patients with CHB treated with ETV or TAF were enrolled. The baseline data of patients with CHB and the clinical characteristics, lipids, and metabolic factors before and approximately 1 year after TAF or ETV treatment were statistically analyzed using SPSS 23.0. In addition, the effects of ETV and TAF on high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol (TCHO) were evaluated using a propensity score-matched model.

Post-treatment TCHO levels were significantly higher in the TAF group than in the ETV group. In the propensity score-matched model, TCHO levels were significantly higher than baseline levels in patients in the TAF treatment group, whereas there was no difference in the ETV group. Using logistic regression analysis, body mass index (BMI), gender and other levels were significantly related to TCHO levels. But 1 year of TAF treatment did not increase the incidence of NAFLD. Therefore, in this study TCHO was higher in patients treated with TAF than in patients with CHB who received ETV, but there was no increase in the incidence of NAFLD due to TAF-induced dyslipidemia.

This is a comprehensive study. TAF has been used as a first-line treatment for HIV and CHB infected patients, and can increase blood lipid levels in HIV patients[2]. In addition to comparing the baseline data and clinical features of patients treated with TAF and ETV, this study compared changes in lipid profiles and determined whether NAFLD increased before and after TAF or ETV therapy. The impact and extent of TAF achieving elevated lipid levels compared with ETV, and the correlation between BMI, gender, hypertension, baseline TCHO, CK-MB levels and elevated TCHO levels were assessed.

The research topic is new. In the context of the increasing prevalence of NAFLD and the 84 million people with HBV infection in China, in addition to existing studies showing that TAF can increase lipid levels in patients with HIV, patients treated with TAF had a greater reduction in their lipid profile than those treated with ETV[3,4]. Limited data are available in terms of the effect of TAF on metabolism-related complications in patients with CHB and the effect of ETV on lipids has not yet been reported in post-marketing studies. Therefore, it is important to investigate whether TAF raises lipid levels and increases the prevalence of NAFLD in patients with CHB compared with ETV.

The study is scientifically sound in methodology. Patients with insufficient years of drug use, interference due to other antiviral drugs or comorbidities associated with other liver-related diseases or heavy alcohol intake were excluded, and 336 CHB patients taking TAF or ETV in a single center were enrolled. They were divided into the group receiving TAF and the group receiving ETV. Pre-treatment lipid profiles and repeat lipid assessments were performed 1 year after the initiation of antiviral therapy. Baseline information and data related to clinical characteristics, metabolic levels, and lipids were collected from the enrolled patients before antiviral therapy and after 1 year of treatment. Statistical analysis was performed using SPSS 23.0. Normally distributed continuous variables were expressed as mean ± SD, Student's t-tests were performed to assess whether the differences in the treatment groups were statistically significant. Categorical variables were described using frequencies and proportions. This article utilized suitable statistical techniques to examine variables within the in-group and components. Differences in each lipid profile component between pre- and post-treatment were calculated, and the data was analyzed using propensity matching score and logistic regression analysis.

The findings of this study are innovative. It was found that CHB patients treated with TAF had higher elevations in TCHO than those treated with ETV and that metabolic factors were associated with elevated TCHO levels. There have studies found that metabolic factors can reduce the danger of hepatocellular carcinoma in patients with HBV[5]. With few studies on the subject, these findings provide guidance for future treatment of patients with CHB combined with NAFLD.

The study has the following shortcomings: The study period was short; whether TAF and ETV can increase the prevalence of NAFLD in patients with CHB was not effectively verified; this study was a single-center retrospective study, which is prone to retrospective bias and selection bias. Therefore, a large-sample multicenter prospective trial is necessary to verify these findings.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

P-Reviewer: Tanaka Y, Japan S-Editor: Qu XL L-Editor: A P-Editor: Qu XL

References
1.  Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol. 2023;15:964-972.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (2)]
2.  Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, DeJesus E, Orkin C, Wohl DA, Brar I, Stephens JL, Girard PM, Huhn G, Plummer A, Liu YP, Cheng AK, McCallister S; GS-US-292-0109 team. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43-52.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 197]  [Cited by in F6Publishing: 193]  [Article Influence: 24.1]  [Reference Citation Analysis (0)]
3.  Lacey A, Savinelli S, Barco EA, Macken A, Cotter AG, Sheehan G, Lambert JS, Muldoon E, Feeney E, Mallon PW, Tinago W; UCD ID Cohort Study. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. AIDS. 2020;34:1161-1170.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 32]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
4.  Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, Borman MA, Lee SS, Myers RP, Coffin CS. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46:599-604.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 38]  [Article Influence: 5.4]  [Reference Citation Analysis (0)]
5.  Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2019;25:52-64.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 44]  [Cited by in F6Publishing: 63]  [Article Influence: 10.5]  [Reference Citation Analysis (0)]